Logo image of PROG

BIORA THERAPEUTICS INC (PROG) Stock Analyst Ratings

USA - Nasdaq - NASDAQ:PROG - US74319F1075 - Common Stock

0.8845
-0.03 (-3.47%)
Last: 5/6/2022, 8:00:02 PM
0.9
+0.02 (+1.75%)
After Hours: 5/6/2022, 8:00:02 PM
Buy % Consensus

83

ChartMill assigns a Buy % Consensus number of 83% to PROG. The Buy consensus is the weighted average rating of the current analysts ratings.

  • Analysts have set a mean price target forecast of 4.08. This target is 361.28% above the current price.
  • PROG was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about PROG.
  • In the previous month the buy percentage consensus was at a similar level.
  • PROG was analyzed by 7 analysts. More opinions would make the average more meaningful.
PROG Historical Analyst RatingsPROG Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -21 -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8 10

Price Target & Forecast

Price Low Median Mean High 0.884.044.084.084.20 - 356.76% 361.28% 361.28% 374.84%
PROG Current Analyst RatingPROG Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0 0 0 0 0
Up and Down Grades
Date Firm Action Rating
2021-10-14 HC Wainwright & Co. Initiate Buy
2021-06-03 Raymond James Downgrade Outperform -> Market Perform
2021-06-03 Baird Downgrade Outperform -> Neutral
2021-05-17 Wells Fargo Maintains Underweight
2021-05-14 Raymond James Maintains Outperform
2021-02-08 Wells Fargo Downgrade Overweight -> Underweight

BIORA THERAPEUTICS INC / PROG FAQ

What is the average price target for BIORA THERAPEUTICS INC (PROG) stock?

7 analysts have analysed PROG and the average price target is 4.08 null. This implies a price increase of 361.28% is expected in the next year compared to the current price of 0.8845.


What is the consensus rating for BIORA THERAPEUTICS INC (PROG) stock?

The consensus rating for BIORA THERAPEUTICS INC (PROG) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.